Infantile ceramidase deficiency (Farber disease) is an uncommon, progressive lysosomal storage disease characterized by multiple ceramide-containing nodules (lipogranulomata) in the subcutaneous tissue and upper aerodigestive tract, painful periarticular swelling, psychomotor retardation, and varying degrees of ocular, pulmonary or hepatic involvement. Management of Farber disease has been limited to symptomatic supportive care, and few affected infants survive beyond 5 years of age. We performed an allogeneic bone marrow transplant (BMT) from an HLA-identical heterozygous sister in a 9.5-month-old female with minimally symptomatic Farber disease who received a pre-transplant regimen of busulfan and cyclophosphamide. Ceramidase activity in peripheral blood leukocytes increased from 6% before transplant to 44% (donor heterozygote level) by 6 weeks after BMT. By 2 months after transplant, the patient's subcutaneous lipogranulomata, pain on joint motion, and hoarseness had resolved. Despite modest gains in cognitive and language development, hypotonia and delayed motor skills persisted. Gradual loss of circulating donor cells with autologous hematopoietic recovery occurred; VNTR analyses showed 50% donor DNA in peripheral blood cells at 8.5 months after BMT and only 1% at 21 months after transplant. Interestingly, leukocyte ceramidase activity consistently remained in the heterozygous range despite attrition of donor cells in peripheral blood. This novel observation indicates ongoing hydrolase production by non-circulating donor cells, possibly in the mononuclear phagocytic system, and uptake by recipient leukocytes. Although lipogranulomata and hoarseness did not recur, the patient's neurological and neurocognitive status progressively declined. She died 28 months after BMT (age 37.5 months) with pulmonary insufficiency caused by recurrent aspiration pneumonias. Allogeneic BMT 
Summary:
Infantile ceramidase deficiency (Farber disease) is an uncommon, progressive lysosomal storage disease characterized by multiple ceramide-containing nodules (lipogranulomata) in the subcutaneous tissue and upper aerodigestive tract, painful periarticular swelling, psychomotor retardation, and varying degrees of ocular, pulmonary or hepatic involvement. Management of Farber disease has been limited to symptomatic supportive care, and few affected infants survive beyond 5 years of age. We performed an allogeneic bone marrow transplant (BMT) from an HLA-identical heterozygous sister in a 9.5-month-old female with minimally symptomatic Farber disease who received a pre-transplant regimen of busulfan and cyclophosphamide. Ceramidase activity in peripheral blood leukocytes increased from 6% before transplant to 44% (donor heterozygote level) by 6 weeks after BMT. By 2 months after transplant, the patient's subcutaneous lipogranulomata, pain on joint motion, and hoarseness had resolved. Despite modest gains in cognitive and language development, hypotonia and delayed motor skills persisted. Gradual loss of circulating donor cells with autologous hematopoietic recovery occurred; VNTR analyses showed 50% donor DNA in peripheral blood cells at 8.5 months after BMT and only 1% at 21 months after transplant. Interestingly, leukocyte ceramidase activity consistently remained in the heterozygous range despite attrition of donor cells in peripheral blood. This novel observation indicates ongoing hydrolase production by non-circulating donor cells, possibly in the mononuclear phagocytic system, and uptake by recipient leukocytes. Although lipogranulomata and hoarseness did not recur, the patient's neurological and neurocognitive status progressively declined. She died 28 months after BMT (age 37.5 months) with pulmonary insufficiency caused by recurrent aspiration pneumonias. Allogeneic BMT Acid ceramidase deficiency (lipogranulomatosis) is an uncommon autosomal recessive lysosomal storage disease with several phenotypes, all of which are characterized by accumulation of the sphingolipid ceramide in cells and tissues.
1,2 Acid ceramidase has been purified, 3 and the gene encoding this hydrolase has been cloned 4 and mapped to chromosomal region 8p21.3-p22. 5 Molecular analyses have identified specific mutations of the acid ceramidase gene among the different disease phenotypes. 4, 5 The infantile phenotype of acid ceramidase deficiency bears the eponym Farber disease and is associated with painful swelling around joints, multiple subcutaneous nodules (lipogranulomata), hoarseness due to lipogranulomata in the upper respiratory tract, psychomotor retardation, and failure to thrive. 6, 7 Recurrent pulmonary infections, aspiration pneumonitis, swallowing difficulties and hepatomegaly are common. Retinal 'cherry red' spots have been described in some cases. Ceramide-laden macrophages are found in the lipogranulomata, lungs and liver. The treatment of infantile ceramidase deficiency has been limited to symptomatic supportive care. Most patients die with progressive disease and profound neurological deterioration at a mean age of 18 to 20 months. 2 Allogeneic bone marrow transplantation (BMT) has been used to provide a cellular source of hydrolase in other lysosomal storage diseases and may be curative in some of these conditions. 8 Allogeneic BMT for infantile ceramidase deficiency has been reported only once before in an 18-month-old patient who had neurological symptoms at the time of transplant and died with progressive neurological deterioration 6 months later. 9 We describe the long-term clinical, biochemical, neurodevelopmental, and neuroradiologic outcomes in an infant with Farber disease who underwent allogeneic BMT from a histocompatible sibling at age 9.5 months and survived until age 37.5 months. Of interest, leukocyte ceramidase activity consistently remained at heterozygous levels despite the gradual and virtually complete loss of donor cells in the peripheral blood, indicating continued production of this hydrolase by noncirculating donor cells and its effective uptake by recipient blood cells.
Case report
The patient was a female infant born at full term (birth weight 3630 g) to healthy unrelated parents whose four other children had no medical or surgical problems. At age 4 months she appeared to have pain on passive movement of her arms. By age 5 months she had pain with both active and passive range of motion of all extremities and had developed mild flexion contractures at the knees, elbows and interphalangeal joints of the fingers, and widening of the wrists and fingers. A magnetic resonance imaging (MRI) study of the brain showed mild generalized volume loss. By age 7 months, the infant had worsening joint pain and contractures and developed hoarseness and hypotonia of the trunk and lower extremities. Subcutaneous nodules had appeared at the proximal interphalangeal and metacarpophalangeal joints (Figure 1a ). The diagnosis of infantile ceramidase deficiency (Farber disease) was confirmed by demonstration of low acid ceramidase activity in peripheral blood leukocytes (0.87 nanomoles substrate cleaved per hour per milligram of protein; 6% of normal) ( Table 1) . Ophthalmoscopic examination, chest radiograph, echocardiogram and abdominal sonogram were all normal. Bronchoscopy was grossly normal, but cytological evaluation of broncho-alveolar lavage fluid showed some lipid-laden pulmonary alveolar macrophages. Motor nerve conduction velocities and electromyogram of the anterior tibial muscle were normal. A repeat brain MRI study when the patient was 9 months old showed normal brain structure and myelination for age but diffuse volume loss and increased size of lateral ventricles and sulci (Figure 2a ). Biochemical and immunogenetic evaluation of the family confirmed that each parent was heterozygous for ceramidase activity and HLA-haploidentical with the patient. The patient was referred for allogeneic BMT from her 3-year-old HLAidentical sister whose leukocyte ceramidase activity was in the heterozygous range.
Methods

Bone marrow transplantation procedure and analysis of engraftment
The protocol and consent forms for the BMT procedure were reviewed and approved by the Human Investigations Committee of Emory University School of Medicine. After informed consent was obtained from her parents, the patient underwent allogeneic BMT at age 9.5 months. She received a pre-transplant conditioning regimen of oral busulfan, 40 mg/m 2 per dose every 6 h for 4 days (16 doses; total + cells, respectively, per kg of recipient weight. After transplant the patient was given granulocyte colony-stimulating factor intravenously until the absolute neutrophil count exceeded 2.0 × 10 9 /l for 2 days. She also received cyclosporine, initially intravenously and then orally, for 6 months after BMT as prophylaxis against acute graft-versus-host disease. Quantitation of donor and recipient cells in the peripheral blood was undertaken at selected times after BMT by assay of leukocyte DNA samples for variable numbers of tandem repeats (VNTR).
11
Pharmacokinetic and biochemical studies Levels of busulfan in the plasma were measured before and at selected times after the first dose, using the gas-liquid chromatographic method previously described. 10, 12 The area under the curve (AUC) was calculated according to the trapezoidal rule using a one-compartment pharmacokinetic model with zero-order absorption. 10, 13 Acid ceramidase activity was measured in peripheral blood leukocytes before and at selected times after BMT using N- [ 17 were also given at each time to evaluate adaptive coping skills. This test provides an overall Adaptive Behavior Composite as well as four subdomain scores: Communication, Daily Living Skills, Socialization and Motor Skills. Results are expressed as standard scores with a mean of 100 and a standard deviation of 15 and as age equivalencies in months. The same examiner (CDC) administered all evaluations using these instruments.
Results
Clinical course
The patient's immediate post-transplant course was uncomplicated, and she was discharged from hospital 19 days after BMT. She did not develop mucositis, hepatic venoocclusive disease, or acute or chronic graft-versus-host disease. The subcutaneous nodules substantially decreased in size by 1 month after BMT and were neither visible nor palpable by 2 months after transplant (Figure 1b) . By that time her hoarseness had completely resolved, and she had increased range of motion at the knees, elbows and interphalangeal joints with less pain on passive range of motion.
By 6 months after BMT, the contractures and joint pains had completely resolved. At that time the patient had some gains in cognitive and language neurodevelopmental milestones, but had persistent hypotonia and only modest improvement in motor skills. Eight and a half months after transplant (age 18 months), she could grasp but not transfer objects, and could sit unassisted but could not stand alone or crawl. Ophthalmological examination, brainstem auditory evoked responses, and electroencephalogram were all normal. At that time her vocalizations and vocabulary had decreased, and she began to have difficulty in swallowing. An oropharyngeal motility study did not demonstrate swallowing dysfunction, nasopharyngeal or gastroesophageal reflux, or aspiration.
By age 19 months the patient's weight, height and head circumference, which previously followed a normal trajectory between the 10th and 25th percentiles for age, 18 had fallen to the fifth percentile. Another swallowing study at age 25.5 months showed severe gastroesophageal reflux and swallowing dyscoordination with tracheal aspiration. A percutaneous gastrostomy tube was placed, and enteral feedings was started. Over the next 18 months the patient's height, weight and head circumference fell to below the fifth percentiles for age (50th percentile for a 12-month-old for height and weight, and 50th percentile for a 17-monthold for head circumference). She developed progressive hypotonia, muscle weakness, loss of head control, inability to sit unassisted, and flexion contractures at the fingers, hips, knees and ankles. New neurological findings included opisthotonus and tongue fasciculations. Ophthalmological examinations and brainstem auditory responses at age 31 months were normal.
The patient required multiple hospitalizations for respiratory distress, bronchospasm and aspiration pneumonias. Despite these and other clinical complications and the loss of circulating donor cells (see below), she never had recurrence of hoarseness or of subcutaneous nodules (Figure 1c) . In view of her progressive neurological and pulmonary deterioration, her parents requested that no resuscitative efforts be performed. The patient died 28 months after BMT (age 37.5 months) with pulmonary failure after another episode of aspiration pneumonitis. No postmortem studies were obtained.
Biochemical and hematologic studies
The AUC for busulfan was 843 mol·min, similar to the median therapeutic AUC (850 mol·min) previously reported in infants and young children receiving this agent before BMT. 10 Engraftment of donor cells was prompt: the absolute neutrophil count exceeded 0.5 × 10 9 /l at 11 days after BMT, and the platelet count exceeded 50 × 10 9 l without transfusions at 14 days after BMT. In the entire post-transplant period the patient required only three trans-fusions of red blood cells and four transfusions of singledonor platelet apheresis products.
Six weeks after transplant, acid ceramidase activity in the peripheral blood leukocytes was 44% of control, similar to levels observed in the heterozygous bone marrow donor. Because post-transplant ceramidase levels had been in the expected donor heterozygous range, no chimerism studies were obtained until 8.5 months after BMT, when leukocyte ceramidase was reported as 18% of the normal control. At that time the VNTR assay on a peripheral blood sample showed 50% donor DNA. Subsequent analyses showed progressive loss of donor cells in the peripheral blood, so that only 1% of donor DNA was found by VNTR at 21 months after BMT. With the exception of the sample obtained at 8.5 months after transplant, however, leukocyte ceramidase activity consistently remained in the heterozygous range throughout the entire post-BMT period, despite autologous hematopoietic recovery and virtually complete absence of circulating donor leukocytes (Table 1) .
Neurodevelopmental status
Pre-transplant neurodevelopmental assessment with the Bayley Scales at age 9 months showed a standard score in the low average range (MDI = 86) with a developmental age equivalence of 7.5 months and a motor standard score (PDI = 76) in the borderline range with a developmental age equivalent of 7 months. Overall adaptive behavior on the VABS showed an age equivalence of 6.5 months. Retesting at 6.5 months after BMT (age 16 months) showed modest gains in cognitive and language development (MDI = 55; age equivalence 9 months) but persistent developmental delay in motor skills (PDI Ͻ50; age equivalence 7 months). Adaptive development also showed positive changes, with overall adaptive behavior equivalent to age 10 months on the VABS. A third assessment at 15.5 months after BMT (age 25 months), when donor cells accounted for less than 10% of peripheral blood leukocytes by VNTR assay, showed declines in the Bayley standard scores into the significantly delayed range and little change in age equivalencies from previous testing (MDI and PDI each Ͻ50; age equivalence, 10 and 7 months, respectively). On the VABS, overall adaptive functioning had declined to an age equivalence of 9 months at this final assessment point.
Neuroradiologic studies
Four months after transplant (age 13.5 months) the MRI showed age-appropriate progression of myelination with stable size of the enlarged ventricles and sulci (Figure 2b ). Eight months after transplant (age 17.5 months), there was diffuse and generalized loss of contrast between gray and white matter on T2-weighted but not T1-weighted images, suggesting an abnormality of myelination; ventricular and sulcal size was unchanged from previous studies (Figure 2c ). The last MRI study, performed 15.5 months after transplant (age 25 months), was not substantially different from the previous examination and showed persistently poor gray-white matter contrast on T2-weighted images only (Figure 2d) . No focal lesions were noted on any brain MRI examinations.
Bone Marrow Transplantation
Discussion
This report provides the first long-term follow-up of allogeneic BMT for infantile ceramidase deficiency in a patient with minimal neurological manifestations at the time of transplant. The previous report of BMT for this condition was in an 18-month-old with obvious neurological abnormalities before transplant. Although that patient's lipogranulomata regressed, he died with progressive neurological deterioration 6 months after transplant. 9 Our patient had prompt and persistent resolution of lipogranulomata, contractures and hoarseness. In the first months after BMT, when donor cells presumably accounted for at least 50% of leukocytes in the peripheral blood, modest improvement in neurocognitive function occurred but no definite improvement in motor skills could be confirmed. The infant's neurological status deteriorated as the level of donor cells in the peripheral blood progressively declined, even though ceramidase activity in circulating recipient leukocytes remained at donor heterozygous levels and neither lipogranulomata nor hoarseness recurred.
The reason for gradual but complete loss of circulating donor hematopoietic cells in this case is not known. Rejection or attrition of related or unrelated hematopoietic cell grafts, usually with autologous hematopoietic reconstitution, is well recognized after allogeneic BMT in other lysosomal storage diseases. Subtherapeutic levels of busulfan in the preparative regimen have been implicated in some of these cases and have been attributed to different busulfan pharmacokinetics in infants and young children vs older children and adults. 10, 13, 19, 20 In our patient, however, busulfan dosage was based on body surface area, 10 and the busulfan AUC was clearly in the therapeutic range. Other factors associated with increased risks of rejection of marrow grafts from HLA-identical siblings include recipient alloimmunization from previous transfusions, depletion of lymphocytes from the allogeneic marrow product, and inadequate immunosuppression before or after BMT. 21 However, none of these adequately explain the gradual loss of donor hematopoietic engraftment in our patient. The infant had not received any transfusions of blood or blood products before BMT. Although we did not determine whether she had cytotoxic antibodies directed against donor lymphocytes, the likelihood of a positive test in this clinical context is remote. The marrow infusion contained a substantial dose of HLA-identical, ABO-compatible donor mononuclear and CD34 + cells and had not been processed for reduction of lymphocytes. Finally, the patient received high-dose cyclophosphamide before BMT and cyclosporine for several months after BMT, with close attention to maintenance of therapeutic cyclosporine levels throughout the post-transplant period.
A novel and instructive observation in this report is the persistence of leukocyte ceramidase activity at donor heterozygous levels despite the loss of circulating donor cells, a phenomenon not previously reported after allogeneic BMT for other lysosomal storage diseases. Clearly, donorderived cells that were not detected in the peripheral blood continued to produce ceramidase, which was then taken up by recipient leukocytes. We hypothesize that donor cells effectively repopulated hepatic Kupffer cells, pulmonary alveolar macrophages, cutaneous Langerhans cells and fixed tissue macrophages, all of which are components of the mononuclear phagocytic (reticuloendothelial) cell system, 22, 23 despite reversion of hematopoiesis to recipient origin. These non-circulating donor cells transferred ceramidase to recipient leukocytes either by direct cell-cell contact or by secretion of hydrolase into the plasma and subsequent endocytosis into the patient's cells. 24 The complete regression of hoarseness and lipogranulomata and the lack of development of interstitial lung disease can thus be explained by persistence of donor macrophages in the submucosal and subcutaneous tissues and by the presence of ceramidase-containing pulmonary alveolar macrophages, respectively.
Despite the persistence of leukocyte ceramidase activity at heterozygous levels, attrition of circulating donor cells was associated with progressive neurological and neurodevelopmental deterioration in this infant with Farber disease. Preclinical studies have shown that microglia, the mononuclear phagocytic cells in the CNS, 25, 26 are gradually and completely replaced by donor-derived cells after BMT [27] [28] [29] [30] and effectively transfer lysosomal hydrolase to recipient neurons in the CNS. 31 Repopulation of the entire microglial compartment after BMT is a four-fold longer process than that for mononuclear phagocytes outside the CNS, 22, 23, 28, 30 and requires at least 1 year in humans. 26 Sustained donor hematopoiesis is apparently required throughout that period to provide adequate numbers of progenitors of these CNS macrophages.
The loss of donor hematopoietic engraftment in our patient prevents definite conclusions about the effect of allogeneic BMT on neurological manifestations of Farber disease. Even with complete and sustained engraftment of normal cells, however, the ability of BMT to stabilize or prevent neurodegeneration in affected infants with minimal neurological abnormalities at the time of transplant is at best questionable. The kinetics of microglial repopulation, as described above, may largely explain the lack of therapeutic effectiveness of BMT in symptomatic infantile ceramidase deficiency and other rapidly progressive infantile phenotypes of sphingolipid storage diseases such as galactosylceramidase deficiency (globoid cell leukodystrophy; Krabbe disease) and arylsulfatase A deficiency (metachromatic leukodystrophy). 26, [32] [33] [34] Allogeneic BMT in these aggressive conditions may stabilize the neurological status only if carried out in truly presymptomatic infants within the first weeks of life, maximizing the time for replacement of microglia with enzymatically normal cells.
The impressive resolution of non-neurological manifestations in both patients with Farber disease supports the potentially curative role of allogeneic BMT in the prolonged-survival form of ceramidase deficiency. [35] [36] [37] Patients with this phenotype may survive into the fourth decade of life and do not have neurological or visceral involvement, but they develop progressive lipogranulomata (often on the eyelids, nares and mouth), hoarseness, laryngeal nodules, joint deformities and contractures. In this situation, transplant-related mortality must be balanced against the progressive disfigurement and loss of joint mobility that occur in this phenotype.
